Renal Cancer - Results from #5300

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial March 17, 2017

Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy March 16, 2017

The therapeutic potential of HIF-2 antagonism in renal cell carcinoma March 16, 2017

Tumor-Infiltrating and Peripheral Blood T Cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma March 16, 2017

Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma March 14, 2017

The longest tumor diameter in one dimension as a predictor for skeletal metastasis in renal cell carcinoma March 14, 2017

Preoperative Albumin to Globulin Ratio (AGR) as Prognostic Factor in Renal Cell Carcinoma March 14, 2017

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor March 13, 2017

Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice March 13, 2017

Dietary inflammatory index and risk of renal cancer in the Iowa Women's Health Study March 10, 2017

Tumor-to-tumor metastases: papillary thyroid carcinoma into a clear cell renal cell carcinoma March 10, 2017

Structured assessment and followup for patients with hereditary kidney tumour syndromes March 9, 2017

Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model March 9, 2017

Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study. March 9, 2017

Irreversible electroporation of small renal masses: suboptimal oncologic efficacy in an early series. March 9, 2017

Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. March 9, 2017

Renal cell carcinoma: molecular characterization and evolving treatment paradigms. March 9, 2017

Update on Renal Mass Biopsy. March 9, 2017

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. March 9, 2017

Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis. March 9, 2017

Page 266 of 456